Allergy Therapeutics (OTCMKTS:AGYTF) vs. Akebia Therapeutics (NASDAQ:AKBA) Financial Review

Allergy Therapeutics (OTCMKTS:AGYTF) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Volatility and Risk

Allergy Therapeutics has a beta of 11.81, indicating that its share price is 1,081% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500.

Insider & Institutional Ownership

33.9% of Akebia Therapeutics shares are held by institutional investors. 4.3% of Akebia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for Allergy Therapeutics and Akebia Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allergy Therapeutics	0	0	0	0	0.00
Akebia Therapeutics	2	0	3	0	2.20

Akebia Therapeutics has a consensus target price of $4.67, indicating a potential upside of 381.25%. Given Akebia Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Akebia Therapeutics is more favorable than Allergy Therapeutics.

Profitability

This table compares Allergy Therapeutics and Akebia Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Allergy Therapeutics	N/A	N/A	N/A
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

Valuation & Earnings

This table compares Allergy Therapeutics and Akebia Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allergy Therapeutics	$71.22 million	1.26	-$51.94 million	N/A	N/A
Akebia Therapeutics	$236.20 million	1.10	-$5.34 million	($0.08)	-12.12

Akebia Therapeutics has higher revenue and earnings than Allergy Therapeutics.

Summary

Akebia Therapeutics beats Allergy Therapeutics on 7 of the 12 factors compared between the two stocks.

About Allergy Therapeutics

Allergy Therapeutics plc engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Acarovac MPL, Venomil, Synbiotics, Penicillin Diagnostics, and Peanut. The company also develops allergy vaccines for grass, tree, and house dust mite, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.

About Akebia Therapeutics

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company’s product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.